MCLA-129

DRUG4 trials

Conditions

Colorectal CancerEsophageal Squamous Cell CarcinomaGastric CancerHead and Neck CancerHead and Neck Squamous Cell CarcinomaNon-Small Cell Lung CancerNon-Small Cell Lung Cancer MetastaticSolid Advanced Tumor

Phase 1

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Active, not recruitingNCT04868877

Merus B.V.Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer +2

Start: 2021-04-28End: 2027-03-01Updated: 2026-02-19

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

RecruitingNCT04930432

Betta Pharmaceuticals Co., Ltd.Colorectal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer +1

Start: 2021-09-24End: 2028-12-30Target: 400Updated: 2026-02-10

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

RecruitingNCT07448116

Betta Pharmaceuticals Co., Ltd.Solid Advanced Tumor

Start: 2026-01-31End: 2029-08-01Target: 164Updated: 2026-03-04

Phase 2

Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

Not yet recruitingNCT06885840

Betta Pharmaceuticals Co., Ltd.Non-Small Cell Lung Cancer

Start: 2025-03-31End: 2028-09-30Target: 100Updated: 2025-03-20

Cancer Research2025-04-21

Neue zielgerichtete Therapien auf dem Prüfstand

Onkologische Welt2024-08-01

Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2024-06-016 citations

Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (<i>MET</i>ex14).

Journal of Clinical Oncology2024-06-013 citations

MCLA-129

Sponsors

Conditions

Phase 1

Phase 2

Related Papers